{
    "xml": "<topic id=\"PHP2958\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/phenytoin\" basename=\"phenytoin\" title=\"PHENYTOIN\">\n<title>PHENYTOIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_284\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/phenytoin\">Phenytoin</xref>\n</p>\n<data name=\"vtmid\">40556005</data>\r\n<data name=\"vtmid\">73585007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_926692410\" title=\"Antiepileptics\">Antiepileptics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP35563\" outputclass=\"indicationsAndDose\" rev=\"1.54\" parent=\"/drugs/phenytoin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Tonic-clonic seizures</p>\n<p outputclass=\"therapeuticIndication\">Focal seizures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years</p>\n<p>Initially 1.5&#8211;2.5&#8239;mg/kg twice daily, then adjusted according to response to 2.5&#8211;5&#8239;mg/kg twice daily (max. per dose 7.5&#8239;mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 75&#8211;150&#8239;mg twice daily, then adjusted according to response to 150&#8211;200&#8239;mg twice daily (max. per dose 300&#8239;mg twice daily), dose also adjusted according to plasma-phenytoin concentration.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 3&#8211;4&#8239;mg/kg daily, alternatively 150&#8211;300&#8239;mg once daily, alternatively 150&#8211;300&#8239;mg daily in 2 divided doses, then increased to 200&#8211;500&#8239;mg daily, to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Status epilepticus</p>\n<p outputclass=\"therapeuticIndication\">Acute symptomatic seizures associated with head trauma or neurosurgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by slow intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Loading dose 20&#8239;mg/kg (max. per dose 2&#8239;g), to be given at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg per minute), to be given with blood pressure and ECG monitoring, then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100&#8239;mg every 6&#8211;8&#8239;hours adjusted according to plasma-concentration monitoring, to be given with blood pressure and ECG monitoring, adjusted according to plasma-phenytoin concentration.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Status epilepticus</p>\n<p outputclass=\"therapeuticIndication\">Acute symptomatic seizures associated with trauma or neurosurgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years</p>\n<p>Loading dose 20&#8239;mg/kg, then 2.5&#8211;5&#8239;mg/kg twice daily, to be given with blood pressure and ECG monitoring.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Loading dose 20&#8239;mg/kg, then up to 100&#8239;mg 3&#8211;4 times a day, to be given with blood pressure and ECG monitoring.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>Preparations containing phenytoin sodium are <b>not</b> bioequivalent to those containing phenytoin base (such as <i>Epanutin Infatabs</i>\n<tm tmtype=\"reg\"/> and <i>Epanutin</i>\n<tm tmtype=\"reg\"/> suspension); 100&#8239;mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92&#8239;mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy, however, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35470\" outputclass=\"unlicensedUse\" rev=\"1.20\" parent=\"/drugs/phenytoin\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use in children</p>\n<p>Licensed for use in children (age range not specified by manufacturer).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Phenytoin doses in BNF publications may differ from those in product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35610\" outputclass=\"contraindications\" rev=\"1.24\" parent=\"/drugs/phenytoin\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<title>General contraindications:</title>\r\n<p>\r\n<ph outputclass=\"contraindication\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n<sectiondiv outputclass=\"additionalContraindications\">\r\n<p outputclass=\"title\">Specific contraindications:</p>\r\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\r\n<p outputclass=\"title\">With intravenous use</p>\r\n<p>\r\n<ph outputclass=\"contraindication\">second- and third-degree heart block</ph>; <ph outputclass=\"contraindication\">sino-atrial block</ph>; <ph outputclass=\"contraindication\">sinus bradycardia</ph>; <ph outputclass=\"contraindication\">Stokes-Adams syndrome</ph>\r\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP35632\" outputclass=\"cautions\" rev=\"1.26\" parent=\"/drugs/phenytoin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<title>General cautions:</title>\n<p>\n<ph outputclass=\"caution\">Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)</ph>\n</p>\n<sectiondiv outputclass=\"additionalCautions\">\n<p outputclass=\"title\">Specific cautions:</p>\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"caution\">heart failure</ph>; <ph outputclass=\"caution\">hypotension</ph>; <ph outputclass=\"caution\">injection solutions alkaline (irritant to tissues)</ph>; <ph outputclass=\"caution\">respiratory depression</ph>; <ph outputclass=\"caution\">resuscitation facilities must be available</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Intramuscular phenytoin should not be used (absorption is slow and erratic).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35555\" outputclass=\"interactions\" rev=\"1.13\" parent=\"/drugs/phenytoin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (phenytoin).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35506\" outputclass=\"sideEffects\" rev=\"1.28\" parent=\"/drugs/phenytoin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acne</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">coarsening of facial appearance</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">gingival hypertrophy and tenderness (maintain good oral hygiene)</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hirsutism</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">transient nervousness</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Leucopenia</ph>; <ph outputclass=\"sideEffect\">aplastic anaemia</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">dyskinesia</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">lupus erythematosus</ph>; <ph outputclass=\"sideEffect\">lymphadenopathy</ph>; <ph outputclass=\"sideEffect\">megaloblastic anaemia</ph>; <ph outputclass=\"sideEffect\">osteomalacia</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">polyarteritis nodosa</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypersensitivity syndrome</ph>; <ph outputclass=\"sideEffect\">interstitial nephritis</ph>; <ph outputclass=\"sideEffect\">pneumonitis</ph>; <ph outputclass=\"sideEffect\">polyarthropathy</ph>; <ph outputclass=\"sideEffect\">suicidal ideation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">alterations in respiratory function</ph>; <ph outputclass=\"sideEffect\">arrhythmias</ph>; <ph outputclass=\"sideEffect\">cardiovascular collapse</ph>; <ph outputclass=\"sideEffect\">cardiovascular depression (particularly if injection too rapid)</ph>; <ph outputclass=\"sideEffect\">CNS depression (particularly if injection too rapid)</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">respiratory arrest</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">purple glove syndrome</ph>; <ph outputclass=\"sideEffect\">tonic seizures</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Reduce rate of administration if bradycardia or hypotension occurs.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hepatotoxicity</p>\n<p>Discontinue immediately and do not re-administer.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsOverdosageInformation\">\n<title>Overdose</title>\n<sectiondiv>\n<p>Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35653\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.21\" parent=\"/drugs/phenytoin\">\n<title>Allergy and cross-sensitivity</title>\n<body>\r\n\r\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\r\n<sectiondiv>\r\n<p>Cross-sensitivity reported with carbamazepine.</p>\r\n<p>Antiepileptic hypersensitivity syndrome associated with phenytoin. See under <xref format=\"dita\" href=\"#PHP78230\" type=\"bookmark\" namespace=\"/treatment-summaries/epilepsy\">Epilepsy</xref> for more information.</p>\n</sectiondiv>\n</section>\r\n</body>\n</topic>\n<topic id=\"PHP35545\" outputclass=\"pregnancy\" parent=\"/drugs/phenytoin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"additionalMonitoringInPregnancy\">\n<sectiondiv>\n<p>Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult&#8212;monitor unbound fraction.</p>\n<p>Doses should be adjusted on the basis of plasma-drug concentration monitoring.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35642\" outputclass=\"breastFeeding\" parent=\"/drugs/phenytoin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Small amounts present in milk, but not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35578\" outputclass=\"hepaticImpairment\" parent=\"/drugs/phenytoin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose to avoid toxicity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35513\" outputclass=\"preTreatmentScreening\" rev=\"1.8\" parent=\"/drugs/phenytoin\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>HLAB* 1502 allele in individuals of Han Chinese or Thai origin&#8212;avoid unless essential (increased risk of Stevens- Johnson syndrome).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35461\" outputclass=\"monitoringRequirements\" parent=\"/drugs/phenytoin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"therapeuticDrugMonitoring\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>The usual total plasma-phenytoin concentration for optimum response is 10&#8211;20&#8239;mg/litre (or 40&#8211;80&#8239;micromol/ litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding.</p>\n<p>Trough plasma concentration for optimum response: neonate&#8211;3 months, 6&#8211;15&#8239;mg/litre (25&#8211;60&#8239;micromol/ litre); child 3 months&#8211;18 years, 10&#8211;20&#8239;mg/litre (40&#8211;80&#8239;micromol/litre).</p>\n</sectiondiv>\n</section>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Manufacturer recommends blood counts (but evidence of practical value uncertain).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Monitor ECG and blood pressure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35665\" outputclass=\"directionsForAdministration\" rev=\"1.22\" parent=\"/drugs/phenytoin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>Before and after administration flush intravenous line with Sodium Chloride 0.9%.</p>\n<p>For <i>intravenous injection</i>, give into a large vein at rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute).</p>\n<p>For <i>intravenous infusion</i>, dilute to a concentration not exceeding 10&#8239;mg/mL with Sodium Chloride 0.9% and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>intravenous infusion</i> (<i>Epanutin</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%. Flush intravenous line with Sodium chloride 0.9% before and after infusion; dilute in 50&#8211;100&#8239;mL infusion fluid (final concentration not to exceed 10&#8239;mg/mL) and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p>\n<p>To avoid local venous irritation each injection or infusion should be preceded and followed by an injection of sterile physiological saline through the same needle or catheter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57714\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.15\" parent=\"/drugs/phenytoin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Switching between formulations </p>\n<p>Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer's product.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35533\" outputclass=\"patientAndCarerAdvice\" rev=\"1.27\" parent=\"/drugs/phenytoin\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Phenytoin for preventing seizures</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures\">www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p outputclass=\"title\">Blood or skin disorders</p>\r\n<p>Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP2958-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/phenytoin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76217\" title=\"Tablet\" namespace=\"/drugs/phenytoin/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76238\" title=\"Chewable tablet\" namespace=\"/drugs/phenytoin/chewable-tablet\">Chewable tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76224\" title=\"Capsule\" namespace=\"/drugs/phenytoin/capsule\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76245\" title=\"Oral suspension\" namespace=\"/drugs/phenytoin/oral-suspension\">Oral suspension</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76231\" title=\"Solution for injection\" namespace=\"/drugs/phenytoin/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97233\" namespace=\"/guidance/prescribing-in-hepatic-impairment\" title=\"Prescribing in hepatic impairment\" count=\"1\" rel=\"backlink\">Prescribing in hepatic impairment</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78143\" namespace=\"/treatment-summaries/contraceptives-interactions\" title=\"Contraceptives, interactions\" count=\"1\" rel=\"backlink\">Contraceptives, interactions</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78157\" namespace=\"/treatment-summaries/neuropathic-pain\" title=\"Neuropathic pain\" count=\"1\" rel=\"backlink\">Neuropathic pain</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78558\" namespace=\"/treatment-summaries/emergency-treatment-of-poisoning\" title=\"Emergency treatment of poisoning\" count=\"1\" rel=\"backlink\">Emergency treatment of poisoning</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_284\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/phenytoin\" title=\"Phenytoin\" count=\"1\" rel=\"link\">Phenytoin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78230\" namespace=\"/treatment-summaries/epilepsy\" title=\"Epilepsy\" count=\"1\" rel=\"link\">Epilepsy</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76217\" namespace=\"/drugs/phenytoin/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76238\" namespace=\"/drugs/phenytoin/chewable-tablet\" title=\"Chewable tablet\" count=\"1\" rel=\"link\">Chewable tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76224\" namespace=\"/drugs/phenytoin/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76245\" namespace=\"/drugs/phenytoin/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76231\" namespace=\"/drugs/phenytoin/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2958",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/phenytoin",
    "basename": "phenytoin",
    "title": "PHENYTOIN",
    "interactants": [
        {
            "id": "bnf_int_284",
            "label": "Phenytoin"
        }
    ],
    "vtmid": "73585007",
    "drugClassification": [
        "Antiepileptics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Tonic-clonic seizures",
                        "html": "Tonic-clonic seizures"
                    },
                    {
                        "textContent": "Focal seizures",
                        "html": "Focal seizures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 1.5&#8211;2.5 mg/kg twice daily, then adjusted according to response to 2.5&#8211;5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300 mg per day.",
                        "html": "<p>Initially 1.5&#8211;2.5&#8239;mg/kg twice daily, then adjusted according to response to 2.5&#8211;5&#8239;mg/kg twice daily (max. per dose 7.5&#8239;mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300&#8239;mg per day.</p>",
                        "ageGroup": "1 month&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 75&#8211;150 mg twice daily, then adjusted according to response to 150&#8211;200 mg twice daily (max. per dose 300 mg twice daily), dose also adjusted according to plasma-phenytoin concentration.",
                        "html": "<p>Initially 75&#8211;150&#8239;mg twice daily, then adjusted according to response to 150&#8211;200&#8239;mg twice daily (max. per dose 300&#8239;mg twice daily), dose also adjusted according to plasma-phenytoin concentration.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 3&#8211;4 mg/kg daily, alternatively 150&#8211;300 mg once daily, alternatively 150&#8211;300 mg daily in 2 divided doses, then increased to 200&#8211;500 mg daily, to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used.",
                        "html": "<p>Initially 3&#8211;4&#8239;mg/kg daily, alternatively 150&#8211;300&#8239;mg once daily, alternatively 150&#8211;300&#8239;mg daily in 2 divided doses, then increased to 200&#8211;500&#8239;mg daily, to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Status epilepticus",
                        "html": "Status epilepticus"
                    },
                    {
                        "textContent": "Acute symptomatic seizures associated with head trauma or neurosurgery",
                        "html": "Acute symptomatic seizures associated with head trauma or neurosurgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially slow intravenous injection or intravenous infusion"
                    ],
                    "textContent": "Initially by slow intravenous injection or by intravenous infusion",
                    "html": "Initially by slow intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Loading dose 20 mg/kg (max. per dose 2 g), to be given at a rate not exceeding 1 mg/kg/minute (max. 50 mg per minute), to be given with blood pressure and ECG monitoring, then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100 mg every 6&#8211;8 hours adjusted according to plasma-concentration monitoring, to be given with blood pressure and ECG monitoring, adjusted according to plasma-phenytoin concentration.",
                        "html": "<p>Loading dose 20&#8239;mg/kg (max. per dose 2&#8239;g), to be given at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg per minute), to be given with blood pressure and ECG monitoring, then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100&#8239;mg every 6&#8211;8&#8239;hours adjusted according to plasma-concentration monitoring, to be given with blood pressure and ECG monitoring, adjusted according to plasma-phenytoin concentration.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Status epilepticus",
                        "html": "Status epilepticus"
                    },
                    {
                        "textContent": "Acute symptomatic seizures associated with trauma or neurosurgery",
                        "html": "Acute symptomatic seizures associated with trauma or neurosurgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By slow intravenous injection or by intravenous infusion",
                    "html": "By slow intravenous injection or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "Loading dose 20 mg/kg, then 2.5&#8211;5 mg/kg twice daily, to be given with blood pressure and ECG monitoring.",
                        "html": "<p>Loading dose 20&#8239;mg/kg, then 2.5&#8211;5&#8239;mg/kg twice daily, to be given with blood pressure and ECG monitoring.</p>",
                        "ageGroup": "1 month&#8211;11 years"
                    },
                    {
                        "textContent": "Loading dose 20 mg/kg, then up to 100 mg 3&#8211;4 times a day, to be given with blood pressure and ECG monitoring.",
                        "html": "<p>Loading dose 20&#8239;mg/kg, then up to 100&#8239;mg 3&#8211;4 times a day, to be given with blood pressure and ECG monitoring.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Preparations containing phenytoin sodium are not bioequivalent to those containing phenytoin base (such as Epanutin Infatabs and Epanutin suspension); 100 mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92 mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy, however, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.",
                "html": "<p>Preparations containing phenytoin sodium are <b>not</b> bioequivalent to those containing phenytoin base (such as <i>Epanutin Infatabs</i>\n<tm tmtype=\"reg\"/> and <i>Epanutin</i>\n<tm tmtype=\"reg\"/> suspension); 100&#8239;mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92&#8239;mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy, however, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With oral use in children",
                    "html": "With <ph outputclass=\"route\">oral</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Licensed for use in children (age range not specified by manufacturer).",
                "html": "<p>Licensed for use in children (age range not specified by manufacturer).</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Phenytoin doses in BNF publications may differ from those in product literature.",
                "html": "<p>Phenytoin doses in BNF publications may differ from those in product literature.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ],
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "second- and third-degree heart block",
                "html": "second- and third-degree heart block",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "sino-atrial block",
                "html": "sino-atrial block",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "sinus bradycardia",
                "html": "sinus bradycardia",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "Stokes-Adams syndrome",
                "html": "Stokes-Adams syndrome",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)",
                "html": "Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)"
            }
        ],
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "heart failure",
                "html": "heart failure",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "hypotension",
                "html": "hypotension",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "injection solutions alkaline (irritant to tissues)",
                "html": "injection solutions alkaline (irritant to tissues)",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "respiratory depression",
                "html": "respiratory depression",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "resuscitation facilities must be available",
                "html": "resuscitation facilities must be available",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.",
                "html": "<p>Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>"
            },
            {
                "type": "importantAdvice",
                "textContent": "Intramuscular phenytoin should not be used (absorption is slow and erratic).",
                "html": "<p>Intramuscular phenytoin should not be used (absorption is slow and erratic).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (phenytoin).",
                "html": "<p>Appendix 1 (phenytoin).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Acne",
                        "html": "Acne",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "coarsening of facial appearance",
                        "html": "coarsening of facial appearance",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gingival hypertrophy and tenderness (maintain good oral hygiene)",
                        "html": "gingival hypertrophy and tenderness (maintain good oral hygiene)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hirsutism",
                        "html": "hirsutism",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "transient nervousness",
                        "html": "transient nervousness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Leucopenia",
                        "html": "Leucopenia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "aplastic anaemia",
                        "html": "aplastic anaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "dyskinesia",
                        "html": "dyskinesia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "lupus erythematosus",
                        "html": "lupus erythematosus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "lymphadenopathy",
                        "html": "lymphadenopathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "megaloblastic anaemia",
                        "html": "megaloblastic anaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "osteomalacia",
                        "html": "osteomalacia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "polyarteritis nodosa",
                        "html": "polyarteritis nodosa",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hypersensitivity syndrome",
                        "html": "Hypersensitivity syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "interstitial nephritis",
                        "html": "interstitial nephritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pneumonitis",
                        "html": "pneumonitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "polyarthropathy",
                        "html": "polyarthropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "suicidal ideation",
                        "html": "suicidal ideation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "alterations in respiratory function",
                        "html": "alterations in respiratory function",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "arrhythmias",
                        "html": "arrhythmias",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "cardiovascular collapse",
                        "html": "cardiovascular collapse",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "cardiovascular depression (particularly if injection too rapid)",
                        "html": "cardiovascular depression (particularly if injection too rapid)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "CNS depression (particularly if injection too rapid)",
                        "html": "CNS depression (particularly if injection too rapid)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "respiratory arrest",
                        "html": "respiratory arrest",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "purple glove syndrome",
                        "html": "purple glove syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "tonic seizures",
                        "html": "tonic seizures",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.",
                "html": "<p>Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.</p>"
            },
            {
                "type": "advice",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Reduce rate of administration if bradycardia or hypotension occurs.",
                "html": "<p>Reduce rate of administration if bradycardia or hypotension occurs.</p>"
            },
            {
                "type": "advice",
                "textContent": "Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.",
                "html": "<p>Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.</p>"
            },
            {
                "type": "advice",
                "title": "Hepatotoxicity",
                "textContent": "Discontinue immediately and do not re-administer.",
                "html": "<p>Discontinue immediately and do not re-administer.</p>"
            }
        ],
        "overdosageInformation": [
            {
                "type": "overdosageInformation",
                "textContent": "Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.",
                "html": "<p>Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.</p>"
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "references": [
                    {
                        "id": "PHP78230",
                        "label": "Epilepsy"
                    }
                ],
                "textContent": "Cross-sensitivity reported with carbamazepine.\n\nAntiepileptic hypersensitivity syndrome associated with phenytoin. See under Epilepsy for more information.",
                "html": "<p>Cross-sensitivity reported with carbamazepine.</p><p>Antiepileptic hypersensitivity syndrome associated with phenytoin. See under <xref format=\"dita\" href=\"#PHP78230\" type=\"bookmark\" namespace=\"/treatment-summaries/epilepsy\">Epilepsy</xref> for more information.</p>"
            }
        ]
    },
    "pregnancy": {
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult&#8212;monitor unbound fraction.\n\nDoses should be adjusted on the basis of plasma-drug concentration monitoring.",
                "html": "<p>Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult&#8212;monitor unbound fraction.</p><p>Doses should be adjusted on the basis of plasma-drug concentration monitoring.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Small amounts present in milk, but not known to be harmful.",
                "html": "<p>Small amounts present in milk, but not known to be harmful.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose to avoid toxicity.",
                "html": "<p>Reduce dose to avoid toxicity.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "HLAB* 1502 allele in individuals of Han Chinese or Thai origin&#8212;avoid unless essential (increased risk of Stevens- Johnson syndrome).",
                "html": "<p>HLAB* 1502 allele in individuals of Han Chinese or Thai origin&#8212;avoid unless essential (increased risk of Stevens- Johnson syndrome).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "therapeuticDrugMonitoring": [
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "The usual total plasma-phenytoin concentration for optimum response is 10&#8211;20 mg/litre (or 40&#8211;80 micromol/ litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.",
                "html": "<p>The usual total plasma-phenytoin concentration for optimum response is 10&#8211;20&#8239;mg/litre (or 40&#8211;80&#8239;micromol/ litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.</p>"
            },
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding.\n\nTrough plasma concentration for optimum response: neonate&#8211;3 months, 6&#8211;15 mg/litre (25&#8211;60 micromol/ litre); child 3 months&#8211;18 years, 10&#8211;20 mg/litre (40&#8211;80 micromol/litre).",
                "html": "<p>Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding.</p><p>Trough plasma concentration for optimum response: neonate&#8211;3 months, 6&#8211;15&#8239;mg/litre (25&#8211;60&#8239;micromol/ litre); child 3 months&#8211;18 years, 10&#8211;20&#8239;mg/litre (40&#8211;80&#8239;micromol/litre).</p>"
            }
        ],
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Manufacturer recommends blood counts (but evidence of practical value uncertain).",
                "html": "<p>Manufacturer recommends blood counts (but evidence of practical value uncertain).</p>"
            },
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Monitor ECG and blood pressure.",
                "html": "<p>Monitor ECG and blood pressure.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Before and after administration flush intravenous line with Sodium Chloride 0.9%.\n\nFor intravenous injection, give into a large vein at rate not exceeding 1 mg/kg/minute (max. 50 mg/minute).\n\nFor intravenous infusion, dilute to a concentration not exceeding 10 mg/mL with Sodium Chloride 0.9% and give into a large vein through an in-line filter (0.22&#8211;0.50 micron) at a rate not exceeding 1 mg/kg/minute (max. 50 mg/minute); complete administration within 1 hour of preparation.",
                "html": "<p>Before and after administration flush intravenous line with Sodium Chloride 0.9%.</p><p>For <i>intravenous injection</i>, give into a large vein at rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute).</p><p>For <i>intravenous infusion</i>, dilute to a concentration not exceeding 10&#8239;mg/mL with Sodium Chloride 0.9% and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Epanutin ), give intermittently in Sodium chloride 0.9%. Flush intravenous line with Sodium chloride 0.9% before and after infusion; dilute in 50&#8211;100 mL infusion fluid (final concentration not to exceed 10 mg/mL) and give into a large vein through an in-line filter (0.22&#8211;0.50 micron) at a rate not exceeding 1 mg/kg/minute (max. 50 mg/minute); complete administration within 1 hour of preparation.\n\nTo avoid local venous irritation each injection or infusion should be preceded and followed by an injection of sterile physiological saline through the same needle or catheter.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Epanutin</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%. Flush intravenous line with Sodium chloride 0.9% before and after infusion; dilute in 50&#8211;100&#8239;mL infusion fluid (final concentration not to exceed 10&#8239;mg/mL) and give into a large vein through an in-line filter (0.22&#8211;0.50&#8239;micron) at a rate not exceeding 1&#8239;mg/kg/minute (max. 50&#8239;mg/minute); complete administration within 1 hour of preparation.</p><p>To avoid local venous irritation each injection or infusion should be preceded and followed by an injection of sterile physiological saline through the same needle or catheter.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Switching between formulations",
                "textContent": "Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer's product.",
                "html": "<p>Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer's product.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures",
                        "label": "www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Phenytoin for preventing seizures",
                "textContent": "www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures\">www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Blood or skin disorders",
                "textContent": "Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).",
                "html": "<p>Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76217",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76238",
                "label": "Chewable tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76224",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76245",
                "label": "Oral suspension",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76231",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP97233",
                "label": "Prescribing in hepatic impairment",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78143",
                "label": "Contraceptives, interactions",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78157",
                "label": "Neuropathic pain",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78558",
                "label": "Emergency treatment of poisoning",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_284",
                "label": "Phenytoin",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78230",
                "label": "Epilepsy",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76217",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76238",
                "label": "Chewable tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76224",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76245",
                "label": "Oral suspension",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76231",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}